Go Pro
NASDAQ:ONCO

Onconetix Q2 2026 Earnings Report

Onconetix logo
$0.88 -0.01 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 +0.01 (+1.20%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Onconetix EPS Results

Actual EPS
-$1.28
Consensus EPS
-$4,505.00
Beat/Miss
Beat by +$4,503.72
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.02 million
Beat/Miss
Missed by -$4.88 thousand
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Onconetix Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile